| Biomarker ID | 115 |
| PMID | 17977648 |
| Year | 2008 |
| Biomarker | ANGPT2, THBS1, CCL5, PTK6, CXCL11, S100P, PSMD5, CDKN2B, PEG3, HTATIP2, CXCL2, RND1, NK4, ACPP, ICAM1, FOSL2, SFN, PLAT, INHBE, CDKN1C, TP73, SOCS2, BMPR1B, CCL2, VIM, SPRY2, CXCL10, LCN2, AKAP12, KLF4, ATF3, FBN1, TWIST1, ALCAM, MSX2, LOX, BTG1, SOCS1, PPP3CA, PPP3CA |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Cell Lines |
| Subjects | Humans |
| Regulation | Downregulated (Log2 fold change: 1.3-7.8 fold) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:- Tie2 signaling,Angiopoietin receptor Tie2-mediated signaling,RAGE pathway,Cell surface interactions at the vascular wall,Oncostatin M |
| Experiment | Androgen Independent PCa Vs Androgen Dependent PCa |
| Type of Biomarker | Prognostic |
| Cohort | Human prostate cancer cell lines (LNCaP-C33, LNCaP-C81, LNCaP-C4-2, PC3 and DU145) were utilized in the study. LNCaP-C33 (androgen-sensitive) and LNCaP-C81 (androgen-independent) cell lines were selected. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | Only PP2A gene was validated on human patient cohort |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on human patient cohort |
| Technical Name | ANGPT2, THBS1, CCL5, PTK6, CXCL11, S100P, PSMD5, CDKN2B, PEG3, HTATIP2, CXCL2, RND1, IL32, ACP3, ICAM1, FOSL2, SFN, PLAT, INHBE, CDKN1C, TP73, SOCS2, BMPR1B, CCL2, VIM, SPRY2, CXCL10, LCN2, AKAP12, KLF4, ATF3, FBN1, TWIST1, ALCAM, MSX2, LOX, BTG1, SOCS1, PPP3CA, PPP3CA |